NMN and NAD+: Why Raising a Biomarker Isn't the Same as Slowing Aging

← Back to articles

Few supplement categories have generated more excitement — or more investor capital — in the last decade than nicotinamide mononucleotide (NMN) and its precursors. Backed by compelling mouse data, an elegant aging theory, and high-profile scientific advocates, NMN became the poster child for the longevity supplement movement. Bottles sell for $60–$120 per month, with marketing that implies they are essentially slowing biological aging itself.

After more than a dozen human clinical trials, the picture looks considerably less exciting than the mouse data suggested. Understanding why requires distinguishing between a biomarker and a health outcome — a distinction that matters enormously in medicine and that the supplement industry routinely exploits.

The NAD+ Theory of Aging: The Science Behind the Hype

NAD+ (nicotinamide adenine dinucleotide) is a coenzyme found in every cell of the body, involved in hundreds of metabolic reactions — most critically in mitochondrial energy production, DNA repair, and the activation of sirtuins (a family of proteins implicated in cellular stress resistance and longevity). NAD+ levels decline with age: a 50-year-old may have roughly half the NAD+ of a 20-year-old in certain tissues.

The theory is straightforward: if NAD+ decline contributes to aging, and if NMN (a dietary precursor to NAD+) raises NAD+ levels, then NMN should slow aging-related deterioration. In mice, this logic held up remarkably well. NMN supplementation in aged rodents improved insulin sensitivity, physical endurance, eye function, energy metabolism, muscle wasting, and bone density — essentially reversing multiple age-related phenotypes. Some of the most influential studies came from David Sinclair's lab at Harvard, whose work generated enormous media coverage and public interest.

The problem is that mice are not humans, and a biomarker change is not a health outcome.

What 12 Human Trials Actually Found

As of early 2024, at least 12 published randomized controlled trials in humans have tested NMN or NR (nicotinamide riboside, a closely related NAD+ precursor). The consistent finding across nearly all of them is: yes, oral NMN and NR reliably raise blood NAD+ levels. A typical trial sees whole-blood NAD+ increase 40–100% over baseline within two to four weeks of supplementation at doses of 300–1000 mg/day. The biomarker moves. Definitively and consistently.

What the trials have not demonstrated, in any robust or replicable way, is that this rise in NAD+ translates into meaningful health outcomes:

• Insulin sensitivity in prediabetic women: A 10-week RCT in Science (Yoshino et al. 2021, Washington University; PMID 33888596) gave 250 mg/day of NMN or placebo to 25 postmenopausal, overweight or obese, prediabetic women. Blood NAD+ rose as expected. Skeletal-muscle insulin sensitivity (the primary endpoint, measured by hyperinsulinemic-euglycemic clamp) went up about 25% in the NMN group and did not change on placebo. But body composition, resting energy use, blood pressure, lipids, and liver or whole-body insulin sensitivity did not improve. A real signal in muscle, not the whole-body rejuvenation the marketing implied.
• Physical performance in older adults: A 2022 Japanese RCT found improvements in gait speed in men over 65 at 250 mg/day of NMN. This is one of the more positive findings in the literature, but it was a small trial (n=42), used a single physical measure, and has not been replicated.
• Metabolism and body composition: Multiple trials measuring waist circumference, fat mass, blood glucose, HbA1c, lipids, and blood pressure have found no significant differences between NMN and placebo.
• Cognitive function: No published RCT has demonstrated NMN-induced improvements in cognitive outcomes in healthy or mildly cognitively impaired adults.
• Biomarkers of cellular aging: Trials measuring telomere length, DNA damage markers, inflammatory cytokines, or epigenetic aging clocks (biological age assessments) have not found consistent improvements attributable to NMN or NR supplementation.

The Biomarker Trap

The fundamental issue is one of the most important lessons in evidence-based medicine: a change in a biomarker is not the same as a change in health. Medical history is littered with cautionary examples. Hormone replacement therapy was adopted based on favorable biomarker changes in cardiovascular risk factors — until large RCTs showed it actually increased cardiovascular events in certain populations. CETP inhibitors raised HDL cholesterol dramatically in trials — and failed to reduce cardiovascular events. Multiple diabetes drugs reduced HbA1c effectively while increasing mortality risk.

NAD+ may be similar. Raising NAD+ in blood or peripheral tissues does not necessarily mean that NAD+ is reaching the tissues where it matters most (the brain, the heart, the liver), because NAD+ itself cannot cross cell membranes — it must be synthesized intracellularly from precursors. Whether supplemental NMN reaches target tissues in meaningful quantities, and whether the cells there can actually use it to improve function, remains genuinely uncertain.

It's also possible that NAD+ decline in aging is a consequence rather than a cause. Aging involves a cascade of interconnected processes; NAD+ levels fall partly because of increased consumption by CD38 (an enzyme dramatically upregulated in aging tissues and chronic inflammation) and PARP enzymes (activated by increasing DNA damage). Supplementing NAD+ precursors without addressing the upstream causes of NAD+ drain may be like refilling a bucket with a hole in the bottom.

The Sinclair Factor and the Hype Machine

David Sinclair's 2019 book "Lifespan" popularized the NAD+ theory for a mass audience and generated enormous commercial interest. Sinclair himself disclosed at the time that he was taking NMN and other supplements and had financial interests in longevity-related companies. Several of the most influential pro-NMN animal studies came from his lab, and some later attracted criticism for reproducibility challenges. This is not to impugn individual researchers — the science of aging is genuinely complex and fast-moving — but the gap between mouse results and media extrapolation was extraordinarily wide and was enthusiastically exploited by a supplement industry that had every financial incentive to do so.

Several prominent aging researchers, including those at the National Institute on Aging, have publicly cautioned that the human evidence does not yet support the commercial claims being made about NMN. A 2023 review in Cell Metabolism noted that while NMN research in preclinical models is legitimately promising, "translating these findings to clinical benefit in humans has proved far more difficult than anticipated."

What the Evidence-Based Position Actually Looks Like

NMN and NR are likely safe at marketed doses — no serious adverse effects have been reported in trials. This makes the decision to take them personal and financially, not medically, risky. If you want to experiment, the honest assessment is: there is a reasonable theoretical basis, there is consistent evidence that NAD+ levels rise, and there is currently insufficient human evidence that this produces any measurable improvement in aging-related outcomes. You are paying $60–$120/month for a biomarker change whose health significance is unproven.

The things that robustly and repeatedly improve aging-related outcomes in human studies are considerably less glamorous: regular aerobic exercise (the most potent known NAD+ booster, incidentally, through activation of NAMPT), caloric moderation and time-restricted eating, smoking cessation, alcohol reduction, high-quality sleep, and management of chronic inflammatory conditions. None of these require a monthly subscription.

Watch this space. The human trial data is still accumulating, and it is possible that the right dose, the right population, or the right combination of interventions will eventually produce the results the mouse data suggested. But we're not there yet, and the supplement industry priced its products as if we were already.